Scholar Rock Wins FDA Approval for First Drug Targeting SMA Muscle Loss

Scholar Rock's Isembyld has received FDA approval as the first drug designed to target muscle loss in spinal muscular atrophy (SMA). In late-stage clinical trials, when combined with an SMN2-targeting therapy, Isembyld significantly improved motor skills in young patients after one year of treatment. This approval represents a major breakthrough for SMA patients, offering a new therapeutic approach that complements existing treatments. The drug's mechanism addresses a different pathway in SMA progression, potentially providing additional benefits for patients seeking comprehensive disease management.